Matsumi Junya, Sato Tetsufumi
Department of Anesthesiology and Intensive Care Medicine, National Cancer Center Hospital, Tokyo, JPN.
Cureus. 2025 Jul 16;17(7):e88128. doi: 10.7759/cureus.88128. eCollection 2025 Jul.
Remimazolam is a newly-approved anesthetic agent, characterized by minimal hemodynamic fluctuations. We present a case of a patient who received three courses of near-infrared photoimmunotherapy for nasopharyngeal cancer. The patient had heart failure with reduced ejection fraction and aortic valve regurgitation. During the first two courses, the patient was anesthetized by sevoflurane with induction of midazolam and opioids and suffered hypotension requiring continuous infusion of noradrenaline. In the third course, the patient was anesthetized with remimazolam and opioids, and showed hemodynamic stability without the use of noradrenaline. This case report suggests the usefulness of remimazolam for hemodynamically vulnerable patients.
瑞马唑仑是一种新获批的麻醉剂，其特点是血流动力学波动极小。我们报告一例接受了三个疗程近红外光免疫疗法治疗鼻咽癌的患者。该患者患有射血分数降低的心力衰竭和主动脉瓣反流。在前两个疗程中，患者使用七氟醚麻醉，并联合咪达唑仑和阿片类药物诱导麻醉，出现了低血压，需要持续输注去甲肾上腺素。在第三个疗程中，患者使用瑞马唑仑和阿片类药物麻醉，血流动力学稳定，无需使用去甲肾上腺素。本病例报告提示瑞马唑仑对血流动力学不稳定的患者有用。
